Page 604 - Read Online

Page 12 of 13 Jiang et al. Hepatoma Res 2020;6:52 I http://dx.doi.org/10.20517/2394-5079.2020.47

Epidemiol 2010;34:550-5.
32. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United
States. Hepatology 2001;33:62-5.
33. De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, et al. Age independent survival benefit for patients with hepatocellular
carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 2020;69:168-76.
34. Witjes CD, Karim-Kos HE, Visser O, van den Akker SA, de Vries E, et al. Hepatocellular carcinoma in a low-endemic area: rising
incidence and improved survival. Eur J Gastroenterol Hepatol 2012;24:450-7.
35. Pavlik T, Majek O, Buchler T, Vyzula R, Petera J, et al. Trends in stage-specific population-based survival of cancer patients in the Czech
Republic in the period 2000-2008. Cancer Epidemiol 2014;38:28-34.
36. Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, et al. Survival in patients with primary liver cancer, gallbladder and
extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: results of EUROCARE-5. Eur J Cancer 2015;51:2169-78.
37. El Mistiri M, Salati M, Marcheselli L, Attia A, Habil S, et al. Cancer incidence, mortality, and survival in Eastern Libya: updated report
from the Benghazi Cancer Registry. Ann Epidemiol 2015;25:564-8.
38. Gondos A, Brenner H, Wabinga H, Parkin DM. Cancer survival in Kampala, Uganda. Br J Cancer 2005;92:1808-12.
39. Peng H, Zheng Y, Wang CF, Gong YM, Wu CX, et al. Survival analysis of liver cancer between 2002 and 2006 in Shanghai. Chin Oncol
2016:561-8.
40. Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL. Survival of liver cancer during 2001-2007 in Qidong city. Chin J Cancer Prevent Treat
2011;18:568-70.
41. Fei FR, Hu RY, Gong WW, Pan J, Wang M. Analysis of mortality and survival rate of liver cancer in Zhejiang Province in China: a
general population-based study. Can J Gastroenterol Hepatol 2019;2019:1074286.
42. Lim GH, Wong CS, Chow KY, Bhalla V, Chia KS. Trends in long-term cancer survival in Singapore: 1968-2002. Ann Acad Med
Singapore 2009;38:99-105.
43. Yang YJ, Bae JM. Survival rates of the 5 major cancers in Jeju Island residents, 2000-2001. J Prev Med Public Health 2007;40:213-7.
44. Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, et al. Long-term survival and conditional survival of cancer patients in Japan using
population-based cancer registry data. Cancer Sci 2014;105:1480-6.
45. Wang QJ, Zhu WX, Li L, Xing XM. Cancer survival in urban Beijing. China Cancer 2001;05:17-8.
46. Zeng HM, Chen WQ, Zheng RS, Zhang SW, Ji JS, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17
population-based cancer registries. Lancet Global Health 2018;6:e555-67.
47. Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, et al. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J Formos
Med Assoc 2016;115:1076-88.
48. Li H, Yang J, Du L, Li Q, Zhu C, et al. Cancer survival in Haining and Jiashan cancer registry areas of Zhejiang Province. China Cancer
2019;29:14-21.
49. He YT, Zeng Y, Xu H, Song G, Tian G, et al. Survival rate among cancer patients in Cixian county, 2000-2002. Chin J Publ Heal
2011;27:1107-10.
50. Li D, Li D, Song G, Liang D, Chen C, et al. Cancer survival in Cixian of China, 2003-2013: a population-based study. Cancer Med
2018;7:1537-45.
51. Luo S, Pan E, He Y, Zhang Q, Wang C, et al. Analysis of survival rates among residents newly diagnosed with malignant cancers during
2010 in Huai’an City. Chin J Cancer Prevent Treat 2016;23:1049-52.
52. Yao HR, Chen H, Chen JG, Zhu J, Zhang YH. Long-term survival trends for liver cancer in Qidong: 1972 to 2011. Chin J Hepatol
2014;22:921-5.
53. He Y, Zhou X, Lv YL. Analysis of the malignant tumor incidence and survival in Jintan district of Changzhou from 2012 to 2013. Jiangsu
J Prevent Med 2019;30:518-21. Available form: http://jsyf.cbpt.cnki.net/WKB2/WebPublication/paperDigest.aspx?paperID=beb308e0-
c2ea-4038-850f-dd73acc4cb9a. [Last accessed on 3 Jul 2020]
54. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
55. Chen JG, Chen HZ, Zhu J, Yang YL, Zhang YH, et al. Cancer survival in patients from a hospital-based cancer registry, China. J Cancer
2018;9:851-60.
56. Engholm G, Gislum M, Bray F, Hakulinen T. Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964-2003
followed up to the end of 2006. Material and methods. Acta Oncologica 2010;49:545-60.
57. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer
2004;40:2307-16.
58. Jarnagin W, Chapman WC, Curley S, D’Angelica M, Rosen C, et al. Surgical treatment of hepatocellular carcinoma: expert consensus
statement. HPB (Oxford) 2010;12:302-10.
59. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, et al. Increased survival of cirrhotic patients with a hepatocellular
carcinoma detected during surveillance. Gastroenterology 2004;126:1005-14.
60. Yun EH, Lim MK, Oh JK, Park JH, Shin A, et al. Combined effect of socioeconomic status, viral hepatitis, and lifestyles on hepatocelluar
carcinoma risk in Korea. Br J Cancer 2010;103:741-6.
61. Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, et al. Race, ethnicity, and socioeconomic status influence the survival of
patients with hepatocellular carcinoma in the United States. Cancer 2010;116:1367-77.
62. Jembere N, Campitelli MA, Sherman M, Feld JJ, Lou W, et al. Influence of socioeconomic status on survival of hepatocellular carcinoma